Posted by Michael Wonder on 03 Oct 2016
NICE says no to daclizumab (Zinbryta)
3 October 2016 - The MS Trust is disappointed that NICE does not intend to recommend that daclizumab (Zinbryta) be made available as a treatment on the NHS in England and Wales.
In the appraisal consultation document published on the NICE website, the appraisal committee's preliminary recommendation states: "Daclizumab is not recommended within its marketing authorisation for treating relapsing forms of multiple sclerosis in adults."
The committee was critical of the analysis submitted by the manufacturer of the cost effectiveness of daclizumab compared with other disease modifying treatments. The MS Trust is reviewing the appraisal documents from NICE and we will respond to the consultation process.
